TNGX
TNGX
NASDAQ · Biotechnology

Tango Therapeutics Inc

$20.98
-0.64 (-2.96%)
As of May 9, 1:33 AM ET ·
Financial Highlights (FY 2026)
Revenue
86.69M
Net Income
-141,186,978
Gross Margin
Profit Margin
-162.9%
Rev Growth
+35.9%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 30.1% 30.1%
Operating Margin -178.4% -160.6% -20.8% -21.5%
Profit Margin -162.9% -154.7% -27.2% -24.1%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 86.69M 63.79M 421.41M 456.66M
Gross Profit 127.00M 137.62M
Operating Income -154,642,890 -102,420,046 -87,784,070 -98,156,679
Net Income -141,186,978 -93,508,190 -114,600,480 -110,156,724
Gross Margin 30.1% 30.1%
Operating Margin -178.4% -160.6% -20.8% -21.5%
Profit Margin -162.9% -154.7% -27.2% -24.1%
Rev Growth +35.9% +35.9% +7.1% +20.2%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 721.39M 673.97M
Total Equity 1.19B 1.15B
D/E Ratio 0.61 0.59
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -145,836,172 -101,953,317 -127,773,532 -138,708,079
Free Cash Flow -89,915,808 -70,983,895